The VERIFY (Vildagliptin Efficacy in Combination with Metformin for Early Treatment of Type 2 Diabetes) trial shows that compared with monotherapy, early combination therapy of metformin with vildagliptin, a once‐daily DPP4 inhibitor, can reduce the probability of initial treatment failure and result in more patients achieving the target blood glucose level.25 This evidence concerns the gene DPP4 and type 2 diabetes mellitus.